Pharma BD Deal Intelligence

Nippon Shinyaku Co., Ltd. / REGENXBIO Inc.

2025 · Licensing/Option · $810M · Pending

REGENXBIO and Nippon Shinyaku entered a Collaboration and License Agreement for the development and commercialization of RGX-121 for Mucopolysaccharidosis II (Hunter syndrome) and RGX-111 for Mucopolysaccharidosis I (Hurler syndrome). REGENXBIO receives $110 million at closing and up to $700 million in milestones ($40 million development and regulatory, $660 million sales) plus double-digit royalties on net sales in the U.S. and certain Asian countries. Nippon Shinyaku leads commercialization in the licensed territory while REGENXBIO leads manufacturing and retains rights to the RGX-121 Priority Review Voucher. The agreement becomes effective on satisfaction of customary closing conditions including Hart-Scott-Rodino clearance.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2030 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2025 deals  ·  Rare Disease deals